GRANTS & FUNDING PROGRAMS AT TRI

In 2015, TRI launched a formal Research Grant Program to support translational research projects based at the institute. The aim is to support researchers progress their discoveries and translate their findings into the clinic.  From 2015-2019, TRI awarded $850,000 via 13 grants, with TRI’s partner institutions and industry collaborators matched this funding with a further $1,571,745. TRI is currently reviewing its Grant Program to ensure it maximises the translational support available to researchers based at the institute. The funding opportunity currently available for eligible recipients is:  

TRI Research Funding  

For teams within TRI seeking funding support for their translational research and/or supporting research grant applications. 

If you are interested in applying for support from TRI please contact [email protected] for a link to the application form.  Applications need to be made three weeks prior to the submission deadline for the relevant grant applications, and must include:

  1. What is novel about the proposal and what is its value-add as a TRI investment for the TRI community.
  2. Previous funding requests to TRI (successful or not) to the same or a different funding body.
  3. How the application meets each of the criteria against which it will be assessed by TRI.
  4. Support from the Institute Director at TRI of the primary applicant (CIA).

    Read the full eligibility criteria and terms and conditions here

    TRI GRANT AND FUNDING RECIPIENTS

    Year awarded

    Grant scheme

    Principal Investigator

    Project title

    2015

    Spore

    Dr Michelle Hill

    Obesity-induced Barrett’s oesophagus and associated cancer: mechanisms and diagnostic tools

    2015

    Spore

    Dr Antje Blumenthal

    Towards biomarkers for patient stratification in sepsis

    2015

    Spore

    Prof Rik Thompson

    Portable, single-sided MRI for routine, low-cost analysis of mammographic density

    2015

    Spore

    Prof Ken O'Byrne

    Nucleoplasmin (NPM)1 a critical repair protein required for genomic stability

    2016

    Spore

    A/Prof Jyotsna Batra

    Novel MicroRNA’s as potential targets for treating prostate cancer

    2016

    Spore

    A/Prof Chamindie Punyadeera

    Circulating Tumour Cells as Biomarkers to Identify Head and Neck Cancer Patients for PD1 Therapy

    2018

    Spore

    Prof Gerald Holtmann

    Modulation of the GI Microbiome with probiotics to treat constipation

    2018

    Spore

    Prof John Hooper

    Theranostic biomolecules for improved diagnosis and treatment of pancreatic cancer

    2018

    Spore

    Dr Arutha Kulasinghe

    Can liquid biopsy provide predictive biomarkers for checkpoint inhibitor response in Non-Small Cell Lung Cancer?

    2018

    Spore

    Prof Peter Soyer

    Towards clinical diagnosis of inflammatory skin rashes using minimally‐invasive micro-sampling technologies

    2019

    Spore

    A/Prof Jyotsna Batra

    Improving the PSA test to detect all lethal prostate cancers

    2019

    Spore

    Prof Ben Panizza

    Therapeutic Potential for the Treatment of Adenoid Cystic Carcinoma (ACC)

    2019

    Drive

    Prof Sandro Porceddu

    Durvax Trial: A Phase 1b, single centre, open label study of a therapeutic Human Papilomavirus (HPC) DNA vaccine co-administered with anti-PD-L1 immunotheraphy, Duravalumab (MED14736), for recurrent and/or metastatic HPV-related oropharnygeal cancer

                                                           

    Looking for funding for your research project: visit the Grant and Funding list page for some helpful links to grant and funding opportunities relevant to research projects at TRI.